Based on the results of research studies, when controlled hormone stimulation of the ovaries is planned based on the ovarian reserve assessment (AMH), it significantly increases a chance of an appropriate response of the patient’s body to medications. When results of AMH and additional tests during hormone therapy are not included, the efficacy may be affected.
The following factors may also be significant in case of failures at the stage of a response to stimulation: selection of a stimulation type, day when treatment was started, presence of an early dominant follicle in the ovary (its activity may inhibit growth of other follicles).
In some patients, a response to stimulation is too poor despite appropriate levels of AMH (approximately 20% of cases, so-called hyporesponders). Abnormalities may also be associated with genes – they may result from polymorphisms or mutations in the genes for hormones such as LH, FSH, oestradiol and other hormones and their receptors.
An abnormal response to stimulation may result in the following, among others: lack of oocytes for collection, obtaining immature cells, hyperstimulation syndrome.